A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Launched by GENENTECH, INC. · Aug 10, 2011
Trial Information
Current as of July 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, ≥18 years of age
- • Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma
- • Ann Arbour Stage III/IV and bulky II (mass \>10 cm)
- • At least one bi-dimensionally measurable lesion defined as \>1.5 cm in its largest dimension by CT scan
- • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- • Left ventricular ejection fraction ≥50%
- • Adequate hematologic function
- Exclusion Criteria:
- • Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy
- • Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation
- • Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma
- • Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
- • Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
- • Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- • History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment
- • Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection
- • Pregnant or lactating women
About Genentech, Inc.
Genentech, Inc. is a leading biotechnology company and a member of the Roche Group, dedicated to transforming the lives of patients with serious medical conditions through innovative therapies. Established in 1976, Genentech is recognized for its pioneering research in biologics and for developing groundbreaking treatments in areas such as oncology, immunology, and neuroscience. With a commitment to scientific excellence and patient-centered care, the company leverages cutting-edge technology and collaborative partnerships to advance drug discovery and development. Genentech's robust pipeline and focus on personalized medicine underscore its mission to address unmet medical needs and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hackensack, New Jersey, United States
New York, New York, United States
San Antonio, Texas, United States
Birmingham, Alabama, United States
Coeur D'alene, Idaho, United States
Worcester, Massachusetts, United States
Ames, Iowa, United States
Farmington, New Mexico, United States
Ann Arbor, Michigan, United States
Norwalk, Connecticut, United States
Yakima, Washington, United States
Las Vegas, Nevada, United States
Aurora, Colorado, United States
Houston, Texas, United States
Tyler, Texas, United States
Louisville, Kentucky, United States
Fort Myers, Florida, United States
Marietta, Georgia, United States
Charleston, South Carolina, United States
Spokane, Washington, United States
Encinitas, California, United States
Saint Petersburg, Florida, United States
Springfield, Oregon, United States
Houston, Texas, United States
Vancouver, Washington, United States
Missoula, Montana, United States
Roanoke, Virginia, United States
Denver, Colorado, United States
Chicago, Illinois, United States
Peoria, Illinois, United States
Basking Ridge, New Jersey, United States
Commack, New York, United States
Rockville Centre, New York, United States
Sleepy Hollow, New York, United States
High Point, North Carolina, United States
Nashville, Tennessee, United States
Fort Worth, Texas, United States
Green Bay, Wisconsin, United States
Patients applied
Trial Officials
Clinical Trials
Study Director
Genentech, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials